

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 29D1096328	(X3) Date Survey Completed 06/08/2026
Name of Provider or Supplier Southwest Medical Associates-Montecito	Street Address, City, State 7061 Grand Montecito Pkwy, Las Vegas, NV	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	This Statement of Deficiencies was generated as a result of the CLIA proficiency testing desk review, conducted off-site for your laboratory on June 8, 2026. The findings and conclusions of any investigation by the Division of Healthcare Purchasing and Compliance shall not be construed as prohibiting any criminal or civil investigations, actions or other claims for relief that may be available to any party under applicable federal, state, or local laws.
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on the findings herein, the Condition: Successful Participation (in a proficiency testing program) was not met. A review of the federal database Certification and

	Survey Provider Enhanced Reporting (CASPER) Report 0155D and the College of American Pathologists (CAP) proficiency testing (PT) evaluation forms on June 8, 2026 found that the laboratory failed to successfully participate in a two of two consecutive PT events. Findings include: The laboratory failed to maintain successful participation with the CAP PT program shown by the unsuccessful performance for two of three PT events for B-Type Natriuretic Peptide (BNP) in the third PT event of 2025 and for the first PT event of 2026. Refer to D2096.
D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a review of the federal database Certification and Survey Provider Enhanced Reporting (CASPER) Report 0155D, a review of the College of American Pathologists (CAP) proficiency testing (PT) evaluation forms on June 8, 2026, the laboratory failed to successfully participate in two of two consecutive proficiency testing events, specifically the 2025 Point of Care Cardiac Markers (PCARM) third event and the 2026 PCARM first event, in the specialty of Routine Chemistry for the analyte B-Type Natriuretic (BNP). Findings include: 1. The laboratory failed to ensure successful participation with the CAP PT program shown by the unsuccessful performance for BNP in the third PT event of 2025 and first PT event 2026. 2. The CASPER Report 0155D reported a score of 0% for the third PT event of 2025 and 0% for the first PT event of 2026. 3. No results were submitted to CAP for the third PT event of 2025 and the first PT Event of 2026.
D6000	MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on the findings herein, the Condition: Laboratories Performing Moderate Complexity Testing; Laboratory Director was not met. A review of the federal database Certification and Survey Provider Enhanced Reporting (CASPER) Report and the College of American Pathologists (CAP) proficiency testing (PT) evaluation forms on June 8, 2026, found that the laboratory director failed to ensure successful participation in two of two consecutive PT events. Findings include: The laboratory director failed to ensure successful participation with the CAP PT program shown by the unsuccessful performance for B-Type Natriuretic Peptide (BNP) in the third PT event of 2025 and for the first PT event of 2026. Refer to D2096.
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this

part;

This STANDARD is not met as evidenced by:

Based on a review of the federal database Certification and Survey Provider Enhanced Reporting (CASPER) Report 0155D, a review of the College of American Pathologists (CAP) proficiency testing (PT) evaluation forms on June 8, 2026, the laboratory failed to successfully participate in two of two consecutive proficiency testing events, specifically the 2025 Point of Care Cardiac Markers (PCARM) third event and the 2026 PCARM first event, in the specialty of Routine Chemistry for the analyte B-Type Natriuretic (BNP). Findings include: 1. The laboratory director failed to ensure successful participation with the CAP PT program shown by the unsuccessful performance for BNP in the third PT event of 2025 and first PT event 2026. 2. The CASPER Report 0155D reported a score of 0% for the third PT event of 2025 and 0% for the first PT event of 2026. 3. No results were submitted to CAP for the third PT event of 2025 and the first PT Event of 2026.